Global Gene Therapy

Gene Therapy Comprehensive Study by Type (Somatic Cell Gene Therapy, Germ Cell Gene Therapy), Application (Neurological Disorders, Rare Diseases, Oncological Disorders, Cardiovascular Diseases, Infectious disease, Other Diseases), Vector Type (Viral Vector, Non-viral Vector) Players and Region - Global Market Outlook to 2030

Gene Therapy Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 19.3%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Gene Therapy
Genes are composed of DNA (Deoxyribonucleic Acid) that contains important information for making proteins which are vital for optimal human body function. Certain gene alterations result in these proteins not being made properly & so can lead to genetic disorders. Gene therapy is a new technique which uses genes to prevent or treat disease. Over the coming years, this technique may permit doctors to treat a disorder by inserting a gene into a patient’s cells rather than using drugs or surgery. This new therapy works by repairing, repressing, or replacing dysfunctional genes which cause disease with aiming of reestablishing normal function. Gene therapy is a striking area for drug development. With the right target & approach, it can address the original cause of a severe diseases.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR19.3%


Major players operating in the global gene therapy market are conducting various clinical and pre-clinical developmental stages of gene therapies. For Instance, In November 2018, Novartis International AG has announced that the EC (European Commission) approved Luxturna, a one time gene therapy aimed at the treatment of patients with vision loss owing to a genetic mutation in both copies of the RPE65 gene as well as who have enough viable retinal cells. The authorization is valid in all 28 member states of the European Commission, & Iceland, Liechtenstein as well as Norway. Luxturna was developed & is commercialized in the United States by Spark Therapeutics. Analyst at AMA Research estimates that French, United Kingdom, and United States Players will contribute the maximum growth to Global Gene Therapy market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Novartis International AG (Switzerland), Kite Pharma, Inc. (United States), Spark Therapeutics Inc. (United States), GlaxoSmithKline PLC (United Kingdom), Bluebird bio Inc. (United States), Genethon (France), Transgene SA (France), Applied Genetic Technologies Corporation (United States), Oxford BioMedica (United Kingdom) and NewLink Genetics Corporation (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Sangamo Therapeutics, Inc. (United States), UniQure N.V (Netherlands) and Celgene Corporation (United States).

Segmentation Overview
AMA Research has segmented the market of Global Gene Therapy market by Type (Somatic Cell Gene Therapy and Germ Cell Gene Therapy), Application (Neurological Disorders, Rare Diseases, Oncological Disorders, Cardiovascular Diseases, Infectious disease and Other Diseases) and Region.

On the basis of application, Oncological Disorders segment is dominating the market in the year 2023

On the basis of geography, the market of Gene Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. If we see Market by Vector Type, the sub-segment i.e. Viral Vector will boost the Gene Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers:
Rising Investment for R&D Activities Relating to Gene Therapy, Growing Prevalence of Cancer and Increasing Awareness Regarding Gene Therapy

Restraints:
High Cost Related With Gene Therapies and Undesirable Immune Responses

Opportunities:
Untapped Potential for Emerging Markets and Ongoing Advancements in Gene Therapy

Market Leaders and their expansionary development strategies
In January 25, 2024, WuXi AppTec and WuXi Advanced Therapies (WAT) enter into a strategic partnership with Rocket Pharmaceuticals to develop and manufacture gene therapies for rare diseases
In October 26, 2023: Thermo Fisher Scientific launches a new single-use bioreactor system designed for the efficient production of viral vectors for gene therapies.


Analyst View
On the basis of vector type, the global gene therapy market is divided into viral vector [Adenoviruses, Retroviruses, Lentiviruses, Adeno Associated Virus, Herpes Simplex Virus, Poxvirus, Vaccinia Virus, and Others], as well as non-viral vector [Gene Gun, Naked/Plasmid Vectors, Electroporation, Lipofection, and Others].

Key Target Audience
Gene Therapy providers, Government and Research Organizations, Industry Associations, Regulatory Bodies, Pharmaceutical Companies and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Somatic Cell Gene Therapy
  • Germ Cell Gene Therapy
By Application
  • Neurological Disorders
  • Rare Diseases
  • Oncological Disorders
  • Cardiovascular Diseases
  • Infectious disease
  • Other Diseases
By Vector Type
  • Viral Vector
  • Non-viral Vector

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Investment for R&D Activities Relating to Gene Therapy
      • 3.2.2. Growing Prevalence of Cancer
      • 3.2.3. Increasing Awareness Regarding Gene Therapy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Gene Therapy, by Type, Application, Vector Type and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Gene Therapy (Value)
      • 5.2.1. Global Gene Therapy by: Type (Value)
        • 5.2.1.1. Somatic Cell Gene Therapy
        • 5.2.1.2. Germ Cell Gene Therapy
      • 5.2.2. Global Gene Therapy by: Application (Value)
        • 5.2.2.1. Neurological Disorders
        • 5.2.2.2. Rare Diseases
        • 5.2.2.3. Oncological Disorders
        • 5.2.2.4. Cardiovascular Diseases
        • 5.2.2.5. Infectious disease
        • 5.2.2.6. Other Diseases
      • 5.2.3. Global Gene Therapy by: Vector Type (Value)
        • 5.2.3.1. Viral Vector
        • 5.2.3.2. Non-viral Vector
      • 5.2.4. Global Gene Therapy Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Gene Therapy (Price)
      • 5.3.1. Global Gene Therapy by: Type (Price)
  • 6. Gene Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis International AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Kite Pharma, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Spark Therapeutics Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline PLC (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bluebird bio Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Genethon (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Transgene SA (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Applied Genetic Technologies Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Oxford BioMedica (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. NewLink Genetics Corporation (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Gene Therapy Sale, by Type, Application, Vector Type and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Gene Therapy (Value)
      • 7.2.1. Global Gene Therapy by: Type (Value)
        • 7.2.1.1. Somatic Cell Gene Therapy
        • 7.2.1.2. Germ Cell Gene Therapy
      • 7.2.2. Global Gene Therapy by: Application (Value)
        • 7.2.2.1. Neurological Disorders
        • 7.2.2.2. Rare Diseases
        • 7.2.2.3. Oncological Disorders
        • 7.2.2.4. Cardiovascular Diseases
        • 7.2.2.5. Infectious disease
        • 7.2.2.6. Other Diseases
      • 7.2.3. Global Gene Therapy by: Vector Type (Value)
        • 7.2.3.1. Viral Vector
        • 7.2.3.2. Non-viral Vector
      • 7.2.4. Global Gene Therapy Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Gene Therapy (Price)
      • 7.3.1. Global Gene Therapy by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Gene Therapy: by Type(USD Million)
  • Table 2. Gene Therapy Somatic Cell Gene Therapy , by Region USD Million (2018-2023)
  • Table 3. Gene Therapy Germ Cell Gene Therapy , by Region USD Million (2018-2023)
  • Table 4. Gene Therapy: by Application(USD Million)
  • Table 5. Gene Therapy Neurological Disorders , by Region USD Million (2018-2023)
  • Table 6. Gene Therapy Rare Diseases , by Region USD Million (2018-2023)
  • Table 7. Gene Therapy Oncological Disorders , by Region USD Million (2018-2023)
  • Table 8. Gene Therapy Cardiovascular Diseases , by Region USD Million (2018-2023)
  • Table 9. Gene Therapy Infectious disease , by Region USD Million (2018-2023)
  • Table 10. Gene Therapy Other Diseases , by Region USD Million (2018-2023)
  • Table 11. Gene Therapy: by Vector Type(USD Million)
  • Table 12. Gene Therapy Viral Vector , by Region USD Million (2018-2023)
  • Table 13. Gene Therapy Non-viral Vector , by Region USD Million (2018-2023)
  • Table 14. South America Gene Therapy, by Country USD Million (2018-2023)
  • Table 15. South America Gene Therapy, by Type USD Million (2018-2023)
  • Table 16. South America Gene Therapy, by Application USD Million (2018-2023)
  • Table 17. South America Gene Therapy, by Vector Type USD Million (2018-2023)
  • Table 18. Brazil Gene Therapy, by Type USD Million (2018-2023)
  • Table 19. Brazil Gene Therapy, by Application USD Million (2018-2023)
  • Table 20. Brazil Gene Therapy, by Vector Type USD Million (2018-2023)
  • Table 21. Argentina Gene Therapy, by Type USD Million (2018-2023)
  • Table 22. Argentina Gene Therapy, by Application USD Million (2018-2023)
  • Table 23. Argentina Gene Therapy, by Vector Type USD Million (2018-2023)
  • Table 24. Rest of South America Gene Therapy, by Type USD Million (2018-2023)
  • Table 25. Rest of South America Gene Therapy, by Application USD Million (2018-2023)
  • Table 26. Rest of South America Gene Therapy, by Vector Type USD Million (2018-2023)
  • Table 27. Asia Pacific Gene Therapy, by Country USD Million (2018-2023)
  • Table 28. Asia Pacific Gene Therapy, by Type USD Million (2018-2023)
  • Table 29. Asia Pacific Gene Therapy, by Application USD Million (2018-2023)
  • Table 30. Asia Pacific Gene Therapy, by Vector Type USD Million (2018-2023)
  • Table 31. China Gene Therapy, by Type USD Million (2018-2023)
  • Table 32. China Gene Therapy, by Application USD Million (2018-2023)
  • Table 33. China Gene Therapy, by Vector Type USD Million (2018-2023)
  • Table 34. Japan Gene Therapy, by Type USD Million (2018-2023)
  • Table 35. Japan Gene Therapy, by Application USD Million (2018-2023)
  • Table 36. Japan Gene Therapy, by Vector Type USD Million (2018-2023)
  • Table 37. India Gene Therapy, by Type USD Million (2018-2023)
  • Table 38. India Gene Therapy, by Application USD Million (2018-2023)
  • Table 39. India Gene Therapy, by Vector Type USD Million (2018-2023)
  • Table 40. South Korea Gene Therapy, by Type USD Million (2018-2023)
  • Table 41. South Korea Gene Therapy, by Application USD Million (2018-2023)
  • Table 42. South Korea Gene Therapy, by Vector Type USD Million (2018-2023)
  • Table 43. Taiwan Gene Therapy, by Type USD Million (2018-2023)
  • Table 44. Taiwan Gene Therapy, by Application USD Million (2018-2023)
  • Table 45. Taiwan Gene Therapy, by Vector Type USD Million (2018-2023)
  • Table 46. Australia Gene Therapy, by Type USD Million (2018-2023)
  • Table 47. Australia Gene Therapy, by Application USD Million (2018-2023)
  • Table 48. Australia Gene Therapy, by Vector Type USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Gene Therapy, by Type USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Gene Therapy, by Application USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Gene Therapy, by Vector Type USD Million (2018-2023)
  • Table 52. Europe Gene Therapy, by Country USD Million (2018-2023)
  • Table 53. Europe Gene Therapy, by Type USD Million (2018-2023)
  • Table 54. Europe Gene Therapy, by Application USD Million (2018-2023)
  • Table 55. Europe Gene Therapy, by Vector Type USD Million (2018-2023)
  • Table 56. Germany Gene Therapy, by Type USD Million (2018-2023)
  • Table 57. Germany Gene Therapy, by Application USD Million (2018-2023)
  • Table 58. Germany Gene Therapy, by Vector Type USD Million (2018-2023)
  • Table 59. France Gene Therapy, by Type USD Million (2018-2023)
  • Table 60. France Gene Therapy, by Application USD Million (2018-2023)
  • Table 61. France Gene Therapy, by Vector Type USD Million (2018-2023)
  • Table 62. Italy Gene Therapy, by Type USD Million (2018-2023)
  • Table 63. Italy Gene Therapy, by Application USD Million (2018-2023)
  • Table 64. Italy Gene Therapy, by Vector Type USD Million (2018-2023)
  • Table 65. United Kingdom Gene Therapy, by Type USD Million (2018-2023)
  • Table 66. United Kingdom Gene Therapy, by Application USD Million (2018-2023)
  • Table 67. United Kingdom Gene Therapy, by Vector Type USD Million (2018-2023)
  • Table 68. Netherlands Gene Therapy, by Type USD Million (2018-2023)
  • Table 69. Netherlands Gene Therapy, by Application USD Million (2018-2023)
  • Table 70. Netherlands Gene Therapy, by Vector Type USD Million (2018-2023)
  • Table 71. Rest of Europe Gene Therapy, by Type USD Million (2018-2023)
  • Table 72. Rest of Europe Gene Therapy, by Application USD Million (2018-2023)
  • Table 73. Rest of Europe Gene Therapy, by Vector Type USD Million (2018-2023)
  • Table 74. MEA Gene Therapy, by Country USD Million (2018-2023)
  • Table 75. MEA Gene Therapy, by Type USD Million (2018-2023)
  • Table 76. MEA Gene Therapy, by Application USD Million (2018-2023)
  • Table 77. MEA Gene Therapy, by Vector Type USD Million (2018-2023)
  • Table 78. Middle East Gene Therapy, by Type USD Million (2018-2023)
  • Table 79. Middle East Gene Therapy, by Application USD Million (2018-2023)
  • Table 80. Middle East Gene Therapy, by Vector Type USD Million (2018-2023)
  • Table 81. Africa Gene Therapy, by Type USD Million (2018-2023)
  • Table 82. Africa Gene Therapy, by Application USD Million (2018-2023)
  • Table 83. Africa Gene Therapy, by Vector Type USD Million (2018-2023)
  • Table 84. North America Gene Therapy, by Country USD Million (2018-2023)
  • Table 85. North America Gene Therapy, by Type USD Million (2018-2023)
  • Table 86. North America Gene Therapy, by Application USD Million (2018-2023)
  • Table 87. North America Gene Therapy, by Vector Type USD Million (2018-2023)
  • Table 88. United States Gene Therapy, by Type USD Million (2018-2023)
  • Table 89. United States Gene Therapy, by Application USD Million (2018-2023)
  • Table 90. United States Gene Therapy, by Vector Type USD Million (2018-2023)
  • Table 91. Canada Gene Therapy, by Type USD Million (2018-2023)
  • Table 92. Canada Gene Therapy, by Application USD Million (2018-2023)
  • Table 93. Canada Gene Therapy, by Vector Type USD Million (2018-2023)
  • Table 94. Mexico Gene Therapy, by Type USD Million (2018-2023)
  • Table 95. Mexico Gene Therapy, by Application USD Million (2018-2023)
  • Table 96. Mexico Gene Therapy, by Vector Type USD Million (2018-2023)
  • Table 97. Gene Therapy: by Type(USD/Units)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Gene Therapy: by Type(USD Million)
  • Table 109. Gene Therapy Somatic Cell Gene Therapy , by Region USD Million (2025-2030)
  • Table 110. Gene Therapy Germ Cell Gene Therapy , by Region USD Million (2025-2030)
  • Table 111. Gene Therapy: by Application(USD Million)
  • Table 112. Gene Therapy Neurological Disorders , by Region USD Million (2025-2030)
  • Table 113. Gene Therapy Rare Diseases , by Region USD Million (2025-2030)
  • Table 114. Gene Therapy Oncological Disorders , by Region USD Million (2025-2030)
  • Table 115. Gene Therapy Cardiovascular Diseases , by Region USD Million (2025-2030)
  • Table 116. Gene Therapy Infectious disease , by Region USD Million (2025-2030)
  • Table 117. Gene Therapy Other Diseases , by Region USD Million (2025-2030)
  • Table 118. Gene Therapy: by Vector Type(USD Million)
  • Table 119. Gene Therapy Viral Vector , by Region USD Million (2025-2030)
  • Table 120. Gene Therapy Non-viral Vector , by Region USD Million (2025-2030)
  • Table 121. South America Gene Therapy, by Country USD Million (2025-2030)
  • Table 122. South America Gene Therapy, by Type USD Million (2025-2030)
  • Table 123. South America Gene Therapy, by Application USD Million (2025-2030)
  • Table 124. South America Gene Therapy, by Vector Type USD Million (2025-2030)
  • Table 125. Brazil Gene Therapy, by Type USD Million (2025-2030)
  • Table 126. Brazil Gene Therapy, by Application USD Million (2025-2030)
  • Table 127. Brazil Gene Therapy, by Vector Type USD Million (2025-2030)
  • Table 128. Argentina Gene Therapy, by Type USD Million (2025-2030)
  • Table 129. Argentina Gene Therapy, by Application USD Million (2025-2030)
  • Table 130. Argentina Gene Therapy, by Vector Type USD Million (2025-2030)
  • Table 131. Rest of South America Gene Therapy, by Type USD Million (2025-2030)
  • Table 132. Rest of South America Gene Therapy, by Application USD Million (2025-2030)
  • Table 133. Rest of South America Gene Therapy, by Vector Type USD Million (2025-2030)
  • Table 134. Asia Pacific Gene Therapy, by Country USD Million (2025-2030)
  • Table 135. Asia Pacific Gene Therapy, by Type USD Million (2025-2030)
  • Table 136. Asia Pacific Gene Therapy, by Application USD Million (2025-2030)
  • Table 137. Asia Pacific Gene Therapy, by Vector Type USD Million (2025-2030)
  • Table 138. China Gene Therapy, by Type USD Million (2025-2030)
  • Table 139. China Gene Therapy, by Application USD Million (2025-2030)
  • Table 140. China Gene Therapy, by Vector Type USD Million (2025-2030)
  • Table 141. Japan Gene Therapy, by Type USD Million (2025-2030)
  • Table 142. Japan Gene Therapy, by Application USD Million (2025-2030)
  • Table 143. Japan Gene Therapy, by Vector Type USD Million (2025-2030)
  • Table 144. India Gene Therapy, by Type USD Million (2025-2030)
  • Table 145. India Gene Therapy, by Application USD Million (2025-2030)
  • Table 146. India Gene Therapy, by Vector Type USD Million (2025-2030)
  • Table 147. South Korea Gene Therapy, by Type USD Million (2025-2030)
  • Table 148. South Korea Gene Therapy, by Application USD Million (2025-2030)
  • Table 149. South Korea Gene Therapy, by Vector Type USD Million (2025-2030)
  • Table 150. Taiwan Gene Therapy, by Type USD Million (2025-2030)
  • Table 151. Taiwan Gene Therapy, by Application USD Million (2025-2030)
  • Table 152. Taiwan Gene Therapy, by Vector Type USD Million (2025-2030)
  • Table 153. Australia Gene Therapy, by Type USD Million (2025-2030)
  • Table 154. Australia Gene Therapy, by Application USD Million (2025-2030)
  • Table 155. Australia Gene Therapy, by Vector Type USD Million (2025-2030)
  • Table 156. Rest of Asia-Pacific Gene Therapy, by Type USD Million (2025-2030)
  • Table 157. Rest of Asia-Pacific Gene Therapy, by Application USD Million (2025-2030)
  • Table 158. Rest of Asia-Pacific Gene Therapy, by Vector Type USD Million (2025-2030)
  • Table 159. Europe Gene Therapy, by Country USD Million (2025-2030)
  • Table 160. Europe Gene Therapy, by Type USD Million (2025-2030)
  • Table 161. Europe Gene Therapy, by Application USD Million (2025-2030)
  • Table 162. Europe Gene Therapy, by Vector Type USD Million (2025-2030)
  • Table 163. Germany Gene Therapy, by Type USD Million (2025-2030)
  • Table 164. Germany Gene Therapy, by Application USD Million (2025-2030)
  • Table 165. Germany Gene Therapy, by Vector Type USD Million (2025-2030)
  • Table 166. France Gene Therapy, by Type USD Million (2025-2030)
  • Table 167. France Gene Therapy, by Application USD Million (2025-2030)
  • Table 168. France Gene Therapy, by Vector Type USD Million (2025-2030)
  • Table 169. Italy Gene Therapy, by Type USD Million (2025-2030)
  • Table 170. Italy Gene Therapy, by Application USD Million (2025-2030)
  • Table 171. Italy Gene Therapy, by Vector Type USD Million (2025-2030)
  • Table 172. United Kingdom Gene Therapy, by Type USD Million (2025-2030)
  • Table 173. United Kingdom Gene Therapy, by Application USD Million (2025-2030)
  • Table 174. United Kingdom Gene Therapy, by Vector Type USD Million (2025-2030)
  • Table 175. Netherlands Gene Therapy, by Type USD Million (2025-2030)
  • Table 176. Netherlands Gene Therapy, by Application USD Million (2025-2030)
  • Table 177. Netherlands Gene Therapy, by Vector Type USD Million (2025-2030)
  • Table 178. Rest of Europe Gene Therapy, by Type USD Million (2025-2030)
  • Table 179. Rest of Europe Gene Therapy, by Application USD Million (2025-2030)
  • Table 180. Rest of Europe Gene Therapy, by Vector Type USD Million (2025-2030)
  • Table 181. MEA Gene Therapy, by Country USD Million (2025-2030)
  • Table 182. MEA Gene Therapy, by Type USD Million (2025-2030)
  • Table 183. MEA Gene Therapy, by Application USD Million (2025-2030)
  • Table 184. MEA Gene Therapy, by Vector Type USD Million (2025-2030)
  • Table 185. Middle East Gene Therapy, by Type USD Million (2025-2030)
  • Table 186. Middle East Gene Therapy, by Application USD Million (2025-2030)
  • Table 187. Middle East Gene Therapy, by Vector Type USD Million (2025-2030)
  • Table 188. Africa Gene Therapy, by Type USD Million (2025-2030)
  • Table 189. Africa Gene Therapy, by Application USD Million (2025-2030)
  • Table 190. Africa Gene Therapy, by Vector Type USD Million (2025-2030)
  • Table 191. North America Gene Therapy, by Country USD Million (2025-2030)
  • Table 192. North America Gene Therapy, by Type USD Million (2025-2030)
  • Table 193. North America Gene Therapy, by Application USD Million (2025-2030)
  • Table 194. North America Gene Therapy, by Vector Type USD Million (2025-2030)
  • Table 195. United States Gene Therapy, by Type USD Million (2025-2030)
  • Table 196. United States Gene Therapy, by Application USD Million (2025-2030)
  • Table 197. United States Gene Therapy, by Vector Type USD Million (2025-2030)
  • Table 198. Canada Gene Therapy, by Type USD Million (2025-2030)
  • Table 199. Canada Gene Therapy, by Application USD Million (2025-2030)
  • Table 200. Canada Gene Therapy, by Vector Type USD Million (2025-2030)
  • Table 201. Mexico Gene Therapy, by Type USD Million (2025-2030)
  • Table 202. Mexico Gene Therapy, by Application USD Million (2025-2030)
  • Table 203. Mexico Gene Therapy, by Vector Type USD Million (2025-2030)
  • Table 204. Gene Therapy: by Type(USD/Units)
  • Table 205. Research Programs/Design for This Report
  • Table 206. Key Data Information from Secondary Sources
  • Table 207. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Gene Therapy: by Type USD Million (2018-2023)
  • Figure 5. Global Gene Therapy: by Application USD Million (2018-2023)
  • Figure 6. Global Gene Therapy: by Vector Type USD Million (2018-2023)
  • Figure 7. South America Gene Therapy Share (%), by Country
  • Figure 8. Asia Pacific Gene Therapy Share (%), by Country
  • Figure 9. Europe Gene Therapy Share (%), by Country
  • Figure 10. MEA Gene Therapy Share (%), by Country
  • Figure 11. North America Gene Therapy Share (%), by Country
  • Figure 12. Global Gene Therapy: by Type USD/Units (2018-2023)
  • Figure 13. Global Gene Therapy share by Players 2023 (%)
  • Figure 14. Global Gene Therapy share by Players (Top 3) 2023(%)
  • Figure 15. Global Gene Therapy share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Novartis International AG (Switzerland) Revenue: by Geography 2023
  • Figure 19. Kite Pharma, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Kite Pharma, Inc. (United States) Revenue: by Geography 2023
  • Figure 21. Spark Therapeutics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Spark Therapeutics Inc. (United States) Revenue: by Geography 2023
  • Figure 23. GlaxoSmithKline PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. GlaxoSmithKline PLC (United Kingdom) Revenue: by Geography 2023
  • Figure 25. Bluebird bio Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Bluebird bio Inc. (United States) Revenue: by Geography 2023
  • Figure 27. Genethon (France) Revenue, Net Income and Gross profit
  • Figure 28. Genethon (France) Revenue: by Geography 2023
  • Figure 29. Transgene SA (France) Revenue, Net Income and Gross profit
  • Figure 30. Transgene SA (France) Revenue: by Geography 2023
  • Figure 31. Applied Genetic Technologies Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 32. Applied Genetic Technologies Corporation (United States) Revenue: by Geography 2023
  • Figure 33. Oxford BioMedica (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. Oxford BioMedica (United Kingdom) Revenue: by Geography 2023
  • Figure 35. NewLink Genetics Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 36. NewLink Genetics Corporation (United States) Revenue: by Geography 2023
  • Figure 37. Global Gene Therapy: by Type USD Million (2025-2030)
  • Figure 38. Global Gene Therapy: by Application USD Million (2025-2030)
  • Figure 39. Global Gene Therapy: by Vector Type USD Million (2025-2030)
  • Figure 40. South America Gene Therapy Share (%), by Country
  • Figure 41. Asia Pacific Gene Therapy Share (%), by Country
  • Figure 42. Europe Gene Therapy Share (%), by Country
  • Figure 43. MEA Gene Therapy Share (%), by Country
  • Figure 44. North America Gene Therapy Share (%), by Country
  • Figure 45. Global Gene Therapy: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Novartis International AG (Switzerland)
  • Kite Pharma, Inc. (United States)
  • Spark Therapeutics Inc. (United States)
  • GlaxoSmithKline PLC (United Kingdom)
  • Bluebird bio Inc. (United States)
  • Genethon (France)
  • Transgene SA (France)
  • Applied Genetic Technologies Corporation (United States)
  • Oxford BioMedica (United Kingdom)
  • NewLink Genetics Corporation (United States)
Additional players considered in the study are as follows:
Sangamo Therapeutics, Inc. (United States) , UniQure N.V (Netherlands) , Celgene Corporation (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 210 Pages 68 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Gene Therapy Quantitative research analysis
Global Gene Therapy Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Novartis International AG (Switzerland), Kite Pharma, Inc. (United States), Spark Therapeutics Inc. (United States), GlaxoSmithKline PLC (United Kingdom), Bluebird bio Inc. (United States), Genethon (France), Transgene SA (France), Applied Genetic Technologies Corporation (United States), Oxford BioMedica (United Kingdom) and NewLink Genetics Corporation (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"" is seen as one of major influencing trends for Gene Therapy Market during projected period 2023-2030.
The Gene Therapy market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Gene Therapy Report?

Have a Query? Click Here

Other Related Reports

Gallbladder Cancer Treatment Comprehensive Study by Type (Gemcitabine, Fluorouracil, Cisplatin, Oxaliplatin, Others (Binimetinib)), End User (Hospitals and Specialty Clinics, Cancer Research and Trea...
$ 3450
Intensive Anti-Aging Treatment Comprehensive Study by Type (Anti-Wrinkle Cream, Anti-stretch Mark Cream, UV absorber, Other), Distribution Channel (Retail Pharmacies, Online Pharmacies, Drug Store) P...
$ 3500
Anticoagulants Comprehensive Study by Type (Vitamin K Antagonists, Non-VKA Oral Anticoagulants, Others), Application (Atrial Fibrillation & Heart Attack, Stroke, Deep Vein Thrombosis (DVT), Pulmonary...
$ 3650
Valerian Oil Comprehensive Study by Type (Solution, Soft Gel Capsule, Others), Application (Pharmaceutical, Aromatherapy, Personal Care, Food & Beverages, Others), Sales Channels (Direct Sales, Indir...
$ 3650
HPV Vaccines Comprehensive Study by Type (Gardasils, Gardasil 9, Cervarix), Age Group (Adolescent, Adults), Disease Indication (Cervical Cancer, Cancer, Vaginal Cancer, Vulvar Cancer, Oropharyngeal C...
$ 3500
Arteriovenous Fistula Treatment Comprehensive Study by Type (Drugs, Transcatheter Embolization, Ultrasound-guided Compression, Surgery), Application (Diagnostic Centers, Hospitals, Clinics, Homecare,...
$ 3750